Study Title:
Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian; Fallopian Tube; or Primary Peritoneal Cancer
Lead Group:
Status:
Review Status: